Patrys Limited
Research Patrys Limited (PAB.AX) on Bullrun: market cap AUD 9.46M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPAB.AX
- ExchangeAU
- CountryAustralia
- CurrencyAUD
- Market capAUD 9.46M
- Financial periodFY2025
- Net income-AUD 3.01M
- Free cash flow-AUD 1.77M
Valuation Snapshot
latest market cap is AUD 9.46M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | -AUD 3.01M | -AUD 1.77M | n/a | 0 | AUD 742.44K | n/a | AUD 732.87K |
| FY2024 | n/a | -AUD 3.54M | -AUD 1.82M | n/a | 0 | AUD 2.24M | n/a | AUD 3.47M |
| FY2023 | n/a | -AUD 7.06M | -AUD 5.78M | n/a | 0 | AUD 3.05M | n/a | AUD 6.84M |
| FY2022 | AUD 27.50K | -AUD 6.78M | -AUD 8.68M | 100.0% | 0 | AUD 7.82M | n/a | AUD 13.43M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-17 | AUD 9.46M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Patrys Limited
Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and inflammatory diseases. The Company's portfolio includes an injectable quetiapine program for the treatment of delirium and its versatile deoxymab antibody platform, including PAT-DX1 and PAT-DX3, which is being developed for applications in inflammatory and autoimmune diseases.
Related stock research
Other related stocks
Frequently asked questions
What is Patrys Limited's market cap?
Patrys Limited's market capitalization is AUD 9.46M.
What does Patrys Limited do?
Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and inflammatory diseases. The Company's portfolio includes an injectable quetiapine program for the treatment of delirium and its versatile deoxymab antibody platform, including PAT-DX1 and PAT-DX3, which is being developed for applications in inflammatory and autoimmune diseases.